Tim Mandelkow
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tim Mandelkow has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Elena Bady
Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
12 shared publications - Guido Sauter
Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
12 shared publications - Maximilian Lennartz
Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
12 shared publications - Niclas C. Blessin
Institute of Pathology University Medical Center Hamburg‐Eppendorf Hamburg Germany
12 shared publications - Ronald Simon
Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
12 shared publications - Magalie C.J. Lurati
Clinical University Hamburg-Eppendorf, Hamburg, Germany
11 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (9)
Organoids Serve as Viable In Vitro Model for Functional Precision Medicine for Mesonephric-Like Adenocarcinoma of the Ovary
- 1 September 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (9)
Open AccessOrganoids Serve as Viable In Vitro Model for Functional Precision Medicine for Mesonephric-Like Adenocarcinoma of the Ovary
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1 - 12, Supplementary Tables 1-5 from BLEACH&STAIN 15-marker Multiplexed Imaging in 3,098 Human Carcinomas Reveals Six Major PD-L1–driven Immune Phenotypes with Distinct Spatial Orchestration
Figure S1a: Representative images of the BLEACH&STAIN 15+1 staining.Figure S1b: BLEACH&STAIN 15+1 validation.Figure S2: Deep learning framework for automated cell type identification.Figure S3: Performance of a Deep Learning-based framework for cell type identification compared to manual set thresholds.Figure S4: Comparison between BLEACH&STAIN and manual PD-L1 assessment.Figure S5: Immune phenotype identification.Figure S6: Association between the immune phenotypes and the individual immune cell parameters.Figure S7: Representative image of the 6 major immune phenotypes of Figure 2Figure S8a: Association between PD-L1 phenotypes and clinico-histopathological parameters.Figure S8b: Distribution of six PD-L1 phenotypes across 44 carcinoma entities.Figure S9: Spatial orchestration of immune cells across the PD-L1 immune phenotypes.Figure S10: Representative image of the spatial orchestration shown in Figure 3Figure S11: Composition of immune cells across the three PD-L1 phenotypesFigure S12: Prognosis analysis of spatial immune parameters in breast cancer for overall 5-years survival after surgery.Table S1: TMA cohort of the PD-L1 15+1 study.Table S2: List of the used antibodies, antigen retrieval (AR), dilutions, and Opal dyes for multiplex fluorescence immunohistochemistry.Table S3: List of 132 immune cell (sub)population.Table S4: Associations between spatial parameters and PD-L1 phenotypes were independent from the used threshold.Table S5: Immune landscape of 3098 human carcinoma samples.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1 - 12, Supplementary Tables 1-5 from BLEACH&STAIN 15-marker Multiplexed Imaging in 3,098 Human Carcinomas Reveals Six Major PD-L1–driven Immune Phenotypes with Distinct Spatial Orchestration
Figure S1a: Representative images of the BLEACH&STAIN 15+1 staining.Figure S1b: BLEACH&STAIN 15+1 validation.Figure S2: Deep learning framework for automated cell type identification.Figure S3: Performance of a Deep Learning-based framework for cell type identification compared to manual set thresholds.Figure S4: Comparison between BLEACH&STAIN and manual PD-L1 assessment.Figure S5: Immune phenotype identification.Figure S6: Association between the immune phenotypes and the individual immune cell parameters.Figure S7: Representative image of the 6 major immune phenotypes of Figure 2Figure S8a: Association between PD-L1 phenotypes and clinico-histopathological parameters.Figure S8b: Distribution of six PD-L1 phenotypes across 44 carcinoma entities.Figure S9: Spatial orchestration of immune cells across the PD-L1 immune phenotypes.Figure S10: Representative image of the spatial orchestration shown in Figure 3Figure S11: Composition of immune cells across the three PD-L1 phenotypesFigure S12: Prognosis analysis of spatial immune parameters in breast cancer for overall 5-years survival after surgery.Table S1: TMA cohort of the PD-L1 15+1 study.Table S2: List of the used antibodies, antigen retrieval (AR), dilutions, and Opal dyes for multiplex fluorescence immunohistochemistry.Table S3: List of 132 immune cell (sub)population.Table S4: Associations between spatial parameters and PD-L1 phenotypes were independent from the used threshold.Table S5: Immune landscape of 3098 human carcinoma samples.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1 - 12, Supplementary Tables 1-5 from BLEACH&STAIN 15-marker multiplexed imaging in 3098 human carcinomas reveals 6 major PD-L1-driven immune phenotypes with distinct spatial orchestration
Figure S1a: Representative images of the BLEACH&STAIN 15+1 staining. Figure S1b: BLEACH&STAIN 15+1 validation. Figure S2: Deep learning framework for automated cell type identification. Figure S3: Performance of a Deep Learning-based framework for cell type identification compared to manual set thresholds. Figure S4: Comparison between BLEACH&STAIN and manual PD-L1 assessment. Figure S5: Immune phenotype identification. Figure S6: Association between the immune phenotypes and the individual immune cell parameters. Figure S7: Representative image of the 6 major immune phenotypes of Figure 2 Figure S8a: Association between PD-L1 phenotypes and clinico-histopathological parameters. Figure S8b: Distribution of six PD-L1 phenotypes across 44 carcinoma entities. Figure S9: Spatial orchestration of immune cells across the PD-L1 immune phenotypes. Figure S10: Representative image of the spatial orchestration shown in Figure 3 Figure S11: Composition of immune cells across the three PD-L1 phenotypes Figure S12: Prognosis analysis of spatial immune parameters in breast cancer for overall 5-years survival after surgery. Table S1: TMA cohort of the PD-L1 15+1 study. Table S2: List of the used antibodies, antigen retrieval (AR), dilutions, and Opal dyes for multiplex fluorescence immunohistochemistry. Table S3: List of 132 immune cell (sub)population. Table S4: Associations between spatial parameters and PD-L1 phenotypes were independent from the used threshold. Table S5: Immune landscape of 3098 human carcinoma samples.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1 - 12, Supplementary Tables 1-5 from BLEACH&STAIN 15-marker multiplexed imaging in 3098 human carcinomas reveals 6 major PD-L1-driven immune phenotypes with distinct spatial orchestration
Figure S1a: Representative images of the BLEACH&STAIN 15+1 staining. Figure S1b: BLEACH&STAIN 15+1 validation. Figure S2: Deep learning framework for automated cell type identification. Figure S3: Performance of a Deep Learning-based framework for cell type identification compared to manual set thresholds. Figure S4: Comparison between BLEACH&STAIN and manual PD-L1 assessment. Figure S5: Immune phenotype identification. Figure S6: Association between the immune phenotypes and the individual immune cell parameters. Figure S7: Representative image of the 6 major immune phenotypes of Figure 2 Figure S8a: Association between PD-L1 phenotypes and clinico-histopathological parameters. Figure S8b: Distribution of six PD-L1 phenotypes across 44 carcinoma entities. Figure S9: Spatial orchestration of immune cells across the PD-L1 immune phenotypes. Figure S10: Representative image of the spatial orchestration shown in Figure 3 Figure S11: Composition of immune cells across the three PD-L1 phenotypes Figure S12: Prognosis analysis of spatial immune parameters in breast cancer for overall 5-years survival after surgery. Table S1: TMA cohort of the PD-L1 15+1 study. Table S2: List of the used antibodies, antigen retrieval (AR), dilutions, and Opal dyes for multiplex fluorescence immunohistochemistry. Table S3: List of 132 immune cell (sub)population. Table S4: Associations between spatial parameters and PD-L1 phenotypes were independent from the used threshold. Table S5: Immune landscape of 3098 human carcinoma samples.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1 - 12, Supplementary Tables 1-5 from BLEACH&STAIN 15-marker multiplexed imaging in 3098 human carcinomas reveals 6 major PD-L1-driven immune phenotypes with distinct spatial orchestration
Figure S1a: Representative images of the BLEACH&STAIN 15+1 staining. Figure S1b: BLEACH&STAIN 15+1 validation. Figure S2: Deep learning framework for automated cell type identification. Figure S3: Performance of a Deep Learning-based framework for cell type identification compared to manual set thresholds. Figure S4: Comparison between BLEACH&STAIN and manual PD-L1 assessment. Figure S5: Immune phenotype identification. Figure S6: Association between the immune phenotypes and the individual immune cell parameters. Figure S7: Representative image of the 6 major immune phenotypes of Figure 2 Figure S8a: Association between PD-L1 phenotypes and clinico-histopathological parameters. Figure S8b: Distribution of six PD-L1 phenotypes across 44 carcinoma entities. Figure S9: Spatial orchestration of immune cells across the PD-L1 immune phenotypes. Figure S10: Representative image of the spatial orchestration shown in Figure 3 Figure S11: Composition of immune cells across the three PD-L1 phenotypes Figure S12: Prognosis analysis of spatial immune parameters in breast cancer for overall 5-years survival after surgery. Table S1: TMA cohort of the PD-L1 15+1 study. Table S2: List of the used antibodies, antigen retrieval (AR), dilutions, and Opal dyes for multiplex fluorescence immunohistochemistry. Table S3: List of 132 immune cell (sub)population. Table S4: Associations between spatial parameters and PD-L1 phenotypes were independent from the used threshold. Table S5: Immune landscape of 3098 human carcinoma samples.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1 - 12, Supplementary Tables 1-5 from BLEACH&STAIN 15-marker multiplexed imaging in 3098 human carcinomas reveals 6 major PD-L1-driven immune phenotypes with distinct spatial orchestration
Figure S1a: Representative images of the BLEACH&STAIN 15+1 staining. Figure S1b: BLEACH&STAIN 15+1 validation. Figure S2: Deep learning framework for automated cell type identification. Figure S3: Performance of a Deep Learning-based framework for cell type identification compared to manual set thresholds. Figure S4: Comparison between BLEACH&STAIN and manual PD-L1 assessment. Figure S5: Immune phenotype identification. Figure S6: Association between the immune phenotypes and the individual immune cell parameters. Figure S7: Representative image of the 6 major immune phenotypes of Figure 2 Figure S8a: Association between PD-L1 phenotypes and clinico-histopathological parameters. Figure S8b: Distribution of six PD-L1 phenotypes across 44 carcinoma entities. Figure S9: Spatial orchestration of immune cells across the PD-L1 immune phenotypes. Figure S10: Representative image of the spatial orchestration shown in Figure 3 Figure S11: Composition of immune cells across the three PD-L1 phenotypes Figure S12: Prognosis analysis of spatial immune parameters in breast cancer for overall 5-years survival after surgery. Table S1: TMA cohort of the PD-L1 15+1 study. Table S2: List of the used antibodies, antigen retrieval (AR), dilutions, and Opal dyes for multiplex fluorescence immunohistochemistry. Table S3: List of 132 immune cell (sub)population. Table S4: Associations between spatial parameters and PD-L1 phenotypes were independent from the used threshold. Table S5: Immune landscape of 3098 human carcinoma samples.
- Open Access
- 1 June 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1 - 12, Supplementary Tables 1-5 from BLEACH&STAIN 15-marker Multiplexed Imaging in 3,098 Human Carcinomas Reveals Six Major PD-L1–driven Immune Phenotypes with Distinct Spatial Orchestration
Figure S1a: Representative images of the BLEACH&STAIN 15+1 staining.Figure S1b: BLEACH&STAIN 15+1 validation.Figure S2: Deep learning framework for automated cell type identification.Figure S3: Performance of a Deep Learning-based framework for cell type identification compared to manual set thresholds.Figure S4: Comparison between BLEACH&STAIN and manual PD-L1 assessment.Figure S5: Immune phenotype identification.Figure S6: Association between the immune phenotypes and the individual immune cell parameters.Figure S7: Representative image of the 6 major immune phenotypes of Figure 2Figure S8a: Association between PD-L1 phenotypes and clinico-histopathological parameters.Figure S8b: Distribution of six PD-L1 phenotypes across 44 carcinoma entities.Figure S9: Spatial orchestration of immune cells across the PD-L1 immune phenotypes.Figure S10: Representative image of the spatial orchestration shown in Figure 3Figure S11: Composition of immune cells across the three PD-L1 phenotypesFigure S12: Prognosis analysis of spatial immune parameters in breast cancer for overall 5-years survival after surgery.Table S1: TMA cohort of the PD-L1 15+1 study.Table S2: List of the used antibodies, antigen retrieval (AR), dilutions, and Opal dyes for multiplex fluorescence immunohistochemistry.Table S3: List of 132 immune cell (sub)population.Table S4: Associations between spatial parameters and PD-L1 phenotypes were independent from the used threshold.Table S5: Immune landscape of 3098 human carcinoma samples.
- 1 June 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1 - 12, Supplementary Tables 1-5 from BLEACH&STAIN 15-marker Multiplexed Imaging in 3,098 Human Carcinomas Reveals Six Major PD-L1–driven Immune Phenotypes with Distinct Spatial Orchestration
Figure S1a: Representative images of the BLEACH&STAIN 15+1 staining.Figure S1b: BLEACH&STAIN 15+1 validation.Figure S2: Deep learning framework for automated cell type identification.Figure S3: Performance of a Deep Learning-based framework for cell type identification compared to manual set thresholds.Figure S4: Comparison between BLEACH&STAIN and manual PD-L1 assessment.Figure S5: Immune phenotype identification.Figure S6: Association between the immune phenotypes and the individual immune cell parameters.Figure S7: Representative image of the 6 major immune phenotypes of Figure 2Figure S8a: Association between PD-L1 phenotypes and clinico-histopathological parameters.Figure S8b: Distribution of six PD-L1 phenotypes across 44 carcinoma entities.Figure S9: Spatial orchestration of immune cells across the PD-L1 immune phenotypes.Figure S10: Representative image of the spatial orchestration shown in Figure 3Figure S11: Composition of immune cells across the three PD-L1 phenotypesFigure S12: Prognosis analysis of spatial immune parameters in breast cancer for overall 5-years survival after surgery.Table S1: TMA cohort of the PD-L1 15+1 study.Table S2: List of the used antibodies, antigen retrieval (AR), dilutions, and Opal dyes for multiplex fluorescence immunohistochemistry.Table S3: List of 132 immune cell (sub)population.Table S4: Associations between spatial parameters and PD-L1 phenotypes were independent from the used threshold.Table S5: Immune landscape of 3098 human carcinoma samples.
- Open Access
- 1 June 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1 - 12, Supplementary Tables 1-5 from BLEACH&STAIN 15-marker Multiplexed Imaging in 3,098 Human Carcinomas Reveals Six Major PD-L1–driven Immune Phenotypes with Distinct Spatial Orchestration
Figure S1a: Representative images of the BLEACH&STAIN 15+1 staining.Figure S1b: BLEACH&STAIN 15+1 validation.Figure S2: Deep learning framework for automated cell type identification.Figure S3: Performance of a Deep Learning-based framework for cell type identification compared to manual set thresholds.Figure S4: Comparison between BLEACH&STAIN and manual PD-L1 assessment.Figure S5: Immune phenotype identification.Figure S6: Association between the immune phenotypes and the individual immune cell parameters.Figure S7: Representative image of the 6 major immune phenotypes of Figure 2Figure S8a: Association between PD-L1 phenotypes and clinico-histopathological parameters.Figure S8b: Distribution of six PD-L1 phenotypes across 44 carcinoma entities.Figure S9: Spatial orchestration of immune cells across the PD-L1 immune phenotypes.Figure S10: Representative image of the spatial orchestration shown in Figure 3Figure S11: Composition of immune cells across the three PD-L1 phenotypesFigure S12: Prognosis analysis of spatial immune parameters in breast cancer for overall 5-years survival after surgery.Table S1: TMA cohort of the PD-L1 15+1 study.Table S2: List of the used antibodies, antigen retrieval (AR), dilutions, and Opal dyes for multiplex fluorescence immunohistochemistry.Table S3: List of 132 immune cell (sub)population.Table S4: Associations between spatial parameters and PD-L1 phenotypes were independent from the used threshold.Table S5: Immune landscape of 3098 human carcinoma samples.
- 1 June 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1 - 12, Supplementary Tables 1-5 from BLEACH&STAIN 15-marker Multiplexed Imaging in 3,098 Human Carcinomas Reveals Six Major PD-L1–driven Immune Phenotypes with Distinct Spatial Orchestration
Figure S1a: Representative images of the BLEACH&STAIN 15+1 staining.Figure S1b: BLEACH&STAIN 15+1 validation.Figure S2: Deep learning framework for automated cell type identification.Figure S3: Performance of a Deep Learning-based framework for cell type identification compared to manual set thresholds.Figure S4: Comparison between BLEACH&STAIN and manual PD-L1 assessment.Figure S5: Immune phenotype identification.Figure S6: Association between the immune phenotypes and the individual immune cell parameters.Figure S7: Representative image of the 6 major immune phenotypes of Figure 2Figure S8a: Association between PD-L1 phenotypes and clinico-histopathological parameters.Figure S8b: Distribution of six PD-L1 phenotypes across 44 carcinoma entities.Figure S9: Spatial orchestration of immune cells across the PD-L1 immune phenotypes.Figure S10: Representative image of the spatial orchestration shown in Figure 3Figure S11: Composition of immune cells across the three PD-L1 phenotypesFigure S12: Prognosis analysis of spatial immune parameters in breast cancer for overall 5-years survival after surgery.Table S1: TMA cohort of the PD-L1 15+1 study.Table S2: List of the used antibodies, antigen retrieval (AR), dilutions, and Opal dyes for multiplex fluorescence immunohistochemistry.Table S3: List of 132 immune cell (sub)population.Table S4: Associations between spatial parameters and PD-L1 phenotypes were independent from the used threshold.Table S5: Immune landscape of 3098 human carcinoma samples.
- Open Access
- 26 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1 - 12, Supplementary Tables 1-5 from BLEACH&STAIN 15-marker Multiplexed Imaging in 3,098 Human Carcinomas Reveals Six Major PD-L1–driven Immune Phenotypes with Distinct Spatial Orchestration
Figure S1a: Representative images of the BLEACH&STAIN 15+1 staining. Figure S1b: BLEACH&STAIN 15+1 validation. Figure S2: Deep learning framework for automated cell type identification. Figure S3: Performance of a Deep Learning-based framework for cell type identification compared to manual set thresholds. Figure S4: Comparison between BLEACH&STAIN and manual PD-L1 assessment. Figure S5: Immune phenotype identification. Figure S6: Association between the immune phenotypes and the individual immune cell parameters. Figure S7: Representative image of the 6 major immune phenotypes of Figure 2 Figure S8a: Association between PD-L1 phenotypes and clinico-histopathological parameters. Figure S8b: Distribution of six PD-L1 phenotypes across 44 carcinoma entities. Figure S9: Spatial orchestration of immune cells across the PD-L1 immune phenotypes. Figure S10: Representative image of the spatial orchestration shown in Figure 3 Figure S11: Composition of immune cells across the three PD-L1 phenotypes Figure S12: Prognosis analysis of spatial immune parameters in breast cancer for overall 5-years survival after surgery. Table S1: TMA cohort of the PD-L1 15+1 study. Table S2: List of the used antibodies, antigen retrieval (AR), dilutions, and Opal dyes for multiplex fluorescence immunohistochemistry. Table S3: List of 132 immune cell (sub)population. Table S4: Associations between spatial parameters and PD-L1 phenotypes were independent from the used threshold. Table S5: Immune landscape of 3098 human carcinoma samples.
- 26 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1 - 12, Supplementary Tables 1-5 from BLEACH&STAIN 15-marker Multiplexed Imaging in 3,098 Human Carcinomas Reveals Six Major PD-L1–driven Immune Phenotypes with Distinct Spatial Orchestration
Figure S1a: Representative images of the BLEACH&STAIN 15+1 staining. Figure S1b: BLEACH&STAIN 15+1 validation. Figure S2: Deep learning framework for automated cell type identification. Figure S3: Performance of a Deep Learning-based framework for cell type identification compared to manual set thresholds. Figure S4: Comparison between BLEACH&STAIN and manual PD-L1 assessment. Figure S5: Immune phenotype identification. Figure S6: Association between the immune phenotypes and the individual immune cell parameters. Figure S7: Representative image of the 6 major immune phenotypes of Figure 2 Figure S8a: Association between PD-L1 phenotypes and clinico-histopathological parameters. Figure S8b: Distribution of six PD-L1 phenotypes across 44 carcinoma entities. Figure S9: Spatial orchestration of immune cells across the PD-L1 immune phenotypes. Figure S10: Representative image of the spatial orchestration shown in Figure 3 Figure S11: Composition of immune cells across the three PD-L1 phenotypes Figure S12: Prognosis analysis of spatial immune parameters in breast cancer for overall 5-years survival after surgery. Table S1: TMA cohort of the PD-L1 15+1 study. Table S2: List of the used antibodies, antigen retrieval (AR), dilutions, and Opal dyes for multiplex fluorescence immunohistochemistry. Table S3: List of 132 immune cell (sub)population. Table S4: Associations between spatial parameters and PD-L1 phenotypes were independent from the used threshold. Table S5: Immune landscape of 3098 human carcinoma samples.
- Open Access
- 26 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1 - 12, Supplementary Tables 1-5 from BLEACH&STAIN 15-marker Multiplexed Imaging in 3,098 Human Carcinomas Reveals Six Major PD-L1–driven Immune Phenotypes with Distinct Spatial Orchestration
Figure S1a: Representative images of the BLEACH&STAIN 15+1 staining. Figure S1b: BLEACH&STAIN 15+1 validation. Figure S2: Deep learning framework for automated cell type identification. Figure S3: Performance of a Deep Learning-based framework for cell type identification compared to manual set thresholds. Figure S4: Comparison between BLEACH&STAIN and manual PD-L1 assessment. Figure S5: Immune phenotype identification. Figure S6: Association between the immune phenotypes and the individual immune cell parameters. Figure S7: Representative image of the 6 major immune phenotypes of Figure 2 Figure S8a: Association between PD-L1 phenotypes and clinico-histopathological parameters. Figure S8b: Distribution of six PD-L1 phenotypes across 44 carcinoma entities. Figure S9: Spatial orchestration of immune cells across the PD-L1 immune phenotypes. Figure S10: Representative image of the spatial orchestration shown in Figure 3 Figure S11: Composition of immune cells across the three PD-L1 phenotypes Figure S12: Prognosis analysis of spatial immune parameters in breast cancer for overall 5-years survival after surgery. Table S1: TMA cohort of the PD-L1 15+1 study. Table S2: List of the used antibodies, antigen retrieval (AR), dilutions, and Opal dyes for multiplex fluorescence immunohistochemistry. Table S3: List of 132 immune cell (sub)population. Table S4: Associations between spatial parameters and PD-L1 phenotypes were independent from the used threshold. Table S5: Immune landscape of 3098 human carcinoma samples.
- 26 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1 - 12, Supplementary Tables 1-5 from BLEACH&STAIN 15-marker Multiplexed Imaging in 3,098 Human Carcinomas Reveals Six Major PD-L1–driven Immune Phenotypes with Distinct Spatial Orchestration
Figure S1a: Representative images of the BLEACH&STAIN 15+1 staining. Figure S1b: BLEACH&STAIN 15+1 validation. Figure S2: Deep learning framework for automated cell type identification. Figure S3: Performance of a Deep Learning-based framework for cell type identification compared to manual set thresholds. Figure S4: Comparison between BLEACH&STAIN and manual PD-L1 assessment. Figure S5: Immune phenotype identification. Figure S6: Association between the immune phenotypes and the individual immune cell parameters. Figure S7: Representative image of the 6 major immune phenotypes of Figure 2 Figure S8a: Association between PD-L1 phenotypes and clinico-histopathological parameters. Figure S8b: Distribution of six PD-L1 phenotypes across 44 carcinoma entities. Figure S9: Spatial orchestration of immune cells across the PD-L1 immune phenotypes. Figure S10: Representative image of the spatial orchestration shown in Figure 3 Figure S11: Composition of immune cells across the three PD-L1 phenotypes Figure S12: Prognosis analysis of spatial immune parameters in breast cancer for overall 5-years survival after surgery. Table S1: TMA cohort of the PD-L1 15+1 study. Table S2: List of the used antibodies, antigen retrieval (AR), dilutions, and Opal dyes for multiplex fluorescence immunohistochemistry. Table S3: List of 132 immune cell (sub)population. Table S4: Associations between spatial parameters and PD-L1 phenotypes were independent from the used threshold. Table S5: Immune landscape of 3098 human carcinoma samples.
- Open Access
- 26 April 2023
- Published by American Association for Cancer Research (AACR)
Data from BLEACH&STAIN 15-marker Multiplexed Imaging in 3,098 Human Carcinomas Reveals Six Major PD-L1–driven Immune Phenotypes with Distinct Spatial Orchestration
Multiplex fluorescence IHC (mfIHC) approaches were yet either limited to six markers or limited to a small tissue size that hampers translational studies on large tissue microarray cohorts. Here we have developed a BLEACH&STAIN mfIHC method that enabled the simultaneous analysis of 15 biomarkers (PD-L1, PD-1, CTLA-4, panCK, CD68, CD163, CD11c, iNOS, CD3, CD8, CD4, FOXP3, CD20, Ki67, and CD31) in 3,098 tumor samples from 44 different carcinoma entities within one week. To facilitate automated immune checkpoint quantification on tumor and immune cells and study its spatial interplay an artificial intelligence–based framework incorporating 17 different deep-learning systems was established. Unsupervised clustering showed that the three PD-L1 phenotypes (PD-L1+ tumor and immune cells, PD-L1+ immune cells, PD-L1−) were either inflamed or noninflamed. In inflamed PD-L1+patients, spatial analysis revealed that an elevated level of intratumoral M2 macrophages as well as CD11c+ dendritic cell (DC) infiltration (P < 0.001 each) was associated with a high CD3+ CD4± CD8± FOXP3± T-cell exclusion and a high PD-1 expression on T cells (P < 0.001 each). In breast cancer, the PD-L1 fluorescence intensity on tumor cells showed a significantly higher predictive performance for overall survival (OS; AUC, 0.72, P < 0.001) compared with the commonly used percentage of PD-L1+ tumor cells (AUC, 0.54). In conclusion, our deep-learning–based BLEACH&STAIN framework facilitates rapid and comprehensive assessment of more than 60 spatially orchestrated immune cell subpopulations and its prognostic relevance.Implications:The development of an easy-to-use high-throughput 15+1 multiplex fluorescence approach facilitates the in-depth understanding of the immune tumor microenvironment (TME) and enables to study the prognostic relevance of more than 130 immune cell subpopulations.
- 26 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from BLEACH&STAIN 15-marker Multiplexed Imaging in 3,098 Human Carcinomas Reveals Six Major PD-L1–driven Immune Phenotypes with Distinct Spatial Orchestration
Multiplex fluorescence IHC (mfIHC) approaches were yet either limited to six markers or limited to a small tissue size that hampers translational studies on large tissue microarray cohorts. Here we have developed a BLEACH&STAIN mfIHC method that enabled the simultaneous analysis of 15 biomarkers (PD-L1, PD-1, CTLA-4, panCK, CD68, CD163, CD11c, iNOS, CD3, CD8, CD4, FOXP3, CD20, Ki67, and CD31) in 3,098 tumor samples from 44 different carcinoma entities within one week. To facilitate automated immune checkpoint quantification on tumor and immune cells and study its spatial interplay an artificial intelligence–based framework incorporating 17 different deep-learning systems was established. Unsupervised clustering showed that the three PD-L1 phenotypes (PD-L1+ tumor and immune cells, PD-L1+ immune cells, PD-L1−) were either inflamed or noninflamed. In inflamed PD-L1+patients, spatial analysis revealed that an elevated level of intratumoral M2 macrophages as well as CD11c+ dendritic cell (DC) infiltration (P < 0.001 each) was associated with a high CD3+ CD4± CD8± FOXP3± T-cell exclusion and a high PD-1 expression on T cells (P < 0.001 each). In breast cancer, the PD-L1 fluorescence intensity on tumor cells showed a significantly higher predictive performance for overall survival (OS; AUC, 0.72, P < 0.001) compared with the commonly used percentage of PD-L1+ tumor cells (AUC, 0.54). In conclusion, our deep-learning–based BLEACH&STAIN framework facilitates rapid and comprehensive assessment of more than 60 spatially orchestrated immune cell subpopulations and its prognostic relevance.Implications:The development of an easy-to-use high-throughput 15+1 multiplex fluorescence approach facilitates the in-depth understanding of the immune tumor microenvironment (TME) and enables to study the prognostic relevance of more than 130 immune cell subpopulations.
- Open Access
- 28 March 2023
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 21 (6) , 605-613
BLEACH&STAIN 15-marker Multiplexed Imaging in 3,098 Human Carcinomas Reveals Six Major PD-L1–driven Immune Phenotypes with Distinct Spatial Orchestration
Multiplex fluorescence IHC (mfIHC) approaches were yet either limited to six markers or limited to a small tissue size that hampers translational studies on large tissue microarray cohorts. Here we have developed a BLEACH&STAIN mfIHC method that enabled the simultaneous analysis of 15 biomarkers (PD-L1, PD-1, CTLA-4, panCK, CD68, CD163, CD11c, iNOS, CD3, CD8, CD4, FOXP3, CD20, Ki67, and CD31) in 3,098 tumor samples from 44 different carcinoma entities within one week. To facilitate automated immune checkpoint quantification on tumor and immune cells and study its spatial interplay an artificial intelligence–based framework incorporating 17 different deep-learning systems was established. Unsupervised clustering showed that the three PD-L1 phenotypes (PD-L1+ tumor and immune cells, PD-L1+ immune cells, PD-L1−) were either inflamed or noninflamed. In inflamed PD-L1+patients, spatial analysis revealed that an elevated level of intratumoral M2 macrophages as well as CD11c+ dendritic cell (DC) infiltration (P < 0.001 each) was associated with a high CD3+ CD4± CD8± FOXP3± T-cell exclusion and a high PD-1 expression on T cells (P < 0.001 each). In breast cancer, the PD-L1 fluorescence intensity on tumor cells showed a significantly higher predictive performance for overall survival (OS; AUC, 0.72, P < 0.001) compared with the commonly used percentage of PD-L1+ tumor cells (AUC, 0.54). In conclusion, our deep-learning–based BLEACH&STAIN framework facilitates rapid and comprehensive assessment of more than 60 spatially orchestrated immune cell subpopulations and its prognostic relevance. Implications: The development of an easy-to-use high-throughput 15+1 multiplex fluorescence approach facilitates the in-depth understanding of the immune tumor microenvironment (TME) and enables to study the prognostic relevance of more than 130 immune cell subpopulations.
- 28 March 2023
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 21 (6) , 605-613
Open AccessBLEACH&STAIN 15-marker Multiplexed Imaging in 3,098 Human Carcinomas Reveals Six Major PD-L1–driven Immune Phenotypes with Distinct Spatial Orchestration
Multiplex fluorescence IHC (mfIHC) approaches were yet either limited to six markers or limited to a small tissue size that hampers translational studies on large tissue microarray cohorts. Here we have developed a BLEACH&STAIN mfIHC method that enabled the simultaneous analysis of 15 biomarkers (PD-L1, PD-1, CTLA-4, panCK, CD68, CD163, CD11c, iNOS, CD3, CD8, CD4, FOXP3, CD20, Ki67, and CD31) in 3,098 tumor samples from 44 different carcinoma entities within one week. To facilitate automated immune checkpoint quantification on tumor and immune cells and study its spatial interplay an artificial intelligence–based framework incorporating 17 different deep-learning systems was established. Unsupervised clustering showed that the three PD-L1 phenotypes (PD-L1+ tumor and immune cells, PD-L1+ immune cells, PD-L1−) were either inflamed or noninflamed. In inflamed PD-L1+patients, spatial analysis revealed that an elevated level of intratumoral M2 macrophages as well as CD11c+ dendritic cell (DC) infiltration (P < 0.001 each) was associated with a high CD3+ CD4± CD8± FOXP3± T-cell exclusion and a high PD-1 expression on T cells (P < 0.001 each). In breast cancer, the PD-L1 fluorescence intensity on tumor cells showed a significantly higher predictive performance for overall survival (OS; AUC, 0.72, P < 0.001) compared with the commonly used percentage of PD-L1+ tumor cells (AUC, 0.54). In conclusion, our deep-learning–based BLEACH&STAIN framework facilitates rapid and comprehensive assessment of more than 60 spatially orchestrated immune cell subpopulations and its prognostic relevance. Implications: The development of an easy-to-use high-throughput 15+1 multiplex fluorescence approach facilitates the in-depth understanding of the immune tumor microenvironment (TME) and enables to study the prognostic relevance of more than 130 immune cell subpopulations.